Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of oral RO7795081 in healthy male participants
NL-OMON60990Phase 1Completed
- Sponsor
- Roche
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of RO7795081 in obesity and type 2 diabetes mellitus (T2DM), sponsored by Roche. Primary endpoint: Primary endpoint(s). Started Feb 2026; status: completed.
02
Drugs
RO7795081
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON60990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60990.